British pharma giant AstraZeneca to invest $2.5 billion in new China hub

British pharma giant AstraZeneca to invest .5 billion in new China hub

Outside the Macclesfield factory of AstraZeneca.

Christopher Furlong | Getty Images News | Getty Images

British pharmaceutical giant AstraZeneca on Friday said that it will invest $2.5 billion in a research and development center in Chinese capital Beijing.

The new hub is expected to take AstraZeneca’s Beijing workforce to around 1,700 employees.

Don’t miss AstraZeneca’s CEO Pascal Soriot interview live on CNBC International at 11:30 a.m. London time / 7:30 a.m. ET.

This breaking news story is being updated.

Source

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to billion

Health

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to $12 billion

January 21, 2026

A startup widely known as “ChatGPT for doctors” raised a new funding round that values the company at $12 billion. OpenEvidence, based in Miami, Florida, closed a $250 million financing, led by Thrive Capital and DST, the company told CNBC. The startup first raised outside capital in February, when it reeled in $75 million from […]

Health

Another alliance of health care and AI signals why pharma stocks should be back in favor

January 20, 2026

Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the latest way health care and artificial intelligence are rapidly intersecting. Bristol Myers said on Tuesday it will work with Microsoft’s AI-powered radiology platform to develop and launch imaging algorithms. These new tools, which can be used to […]

Health

Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry

January 20, 2026

US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers […]